by Steven Grossman | Nov 11, 2025 | Short Takes and Updates
Over the past two weeks, several news stories have reported low morale at FDA. Although they all reached the same conclusion, each story focused on a different driver. One was about how the shutdown was exacerbating low morale; another focused on the cumulative impact...
by Steven Grossman | Nov 11, 2025 | Uncategorized
This week’s questions:Any initial thoughts on CDER Director George Tidmarsh’s response to being accused of abusing his office?Your column on national uniformity and federal preemption (here) was critical of both industry and consumer advocates who are involved in the...
by Steven Grossman | Nov 3, 2025 | Uncategorized
This week’s questions:What do you think about this past week’s stories on increased lobbying by pharma (and others) this year? Why was your analysis (here) of the nine vouchers awarded under the National Priority Review Voucher Initiative more positive than most? Q:...
by Steven Grossman | Oct 31, 2025 | Short Takes and Updates
To keep our country safe, counterterrorism efforts must be operational and effective 24/7/365. It only takes one terrorist at one specific moment to create a catastrophe.When it comes to food and medical products, FDA is our nation’s Department of Homeland Security....
by Steven Grossman | Oct 27, 2025 | Uncategorized
This week’s questions:It appears that no progress has been made to end the federal government shutdown. What happens next? There have been recent headlines that FDA’s FY 26 funding might be appropriated, separate from resolution of the shutdown. Is this true and...
